VK 1430
Alternative Names: VK-1430Latest Information Update: 24 Mar 2023
Price :
$50 *
At a glance
- Originator Ligand Pharmaceuticals
- Developer Viking Therapeutics
- Class Antihyperlipidaemics; Hepatoprotectants; Small molecules
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dyslipidaemias; Hypertriglyceridaemia; Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 14 Mar 2023 Viking Therapeutics receives patent allowance for VK 1430 in Hong Kong, Europe and the US
- 14 Mar 2023 Preclinical trials in Dyslipidaemias in USA (PO) (Viking Therapeutics pipeline, March 2023)
- 14 Mar 2023 Preclinical trials in Obesity in USA (PO) (Viking Therapeutics pipeline, March 2023)